6 [11] E. Maiani, M. Diederich, and S. Gonﬂoni, “DNA damage response: the emerging role of c-Abl as a regulatory switch?” Biochemical Pharmacology, vol. 82, pp. 1269–1276, 2011. [12] S. Z. Imam, F. E. Indig, W. H. Cheng et al., “Cockayne syn- drome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase,” Nucleic Acids Research, vol. 35, no. 15, pp. 4941–4951, 2007. [13] B. D’Autre´aux and M. B. Toledano, “ROS as signalling molecules: mechanisms that generate speciﬁcity in ROS homeostasis,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 813–824, 2007. [14] X. Sun, F. Wu, R. Datta, S. Kharbanda, and D. Kufe, “Inter- action between protein kinase C δ and the c-Abl tyrosine kin- ase in the cellular response to oxidative stress,” The Journal of Biological Chemistry, vol. 275, no. 11, pp. 7470–7473, 2000. [15] C. Cao, X. Ren, S. Kharbanda, A. Koleske, K. V. S. Prasad, and D. Kufe, “The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress,” The Journal of Biological Chemistry, vol. 276, no. 15, pp. 11465–11468, 2001. [16] C. Cao, Y. Leng, X. Liu, Y. Yi, P. Li, and D. Kufe, “Catalase is regulated by ubiquitination and proteosomal degradation. Role of the c-Abl and Arg tyrosine kinases,” Biochemistry, vol. 42, no. 35, pp. 10348–10353, 2003. [17] B. Li, X. Wang, N. Rasheed et al., “Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C δ,” Genes and Development, vol. 18, no. 15, pp. 1824– 1837, 2004. [18] S. T. Wen and R. A. Van Etten, “The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity,” Genes and Development, vol. 11, no. 19, pp. 2456–2467, 1997. [19] C. Cao, Y. Leng, W. Huang, X. Liu, and D. Kufe, “Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases,” The Journal of Biological Chemistry, vol. 278, no. 41, pp. 39609–39614, 2003. [20] A. K. Leonberg and Y. C. Chai, “The functional role of cysteine residues for c-Abl kinase activity,” Molecular and Cellular Biochemistry, vol. 304, no. 1-2, pp. 207–212, 2007. [21] S. D. Schlatterer, M. A. Tremblay, C. M. Acker, and P. Davies, “Neuronal c-Abl overexpression leads to neuronal loss and neuroinﬂammation in the mouse forebrain,” Journal of Alzheimer’s Disease, vol. 25, no. 1, pp. 119–133, 2011. [22] K. Yoshida, T. Yamaguchi, T. Natsume, D. Kufe, and Y. Miki, “JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage,” Nature Cell Biology, vol. 7, no. 3, pp. 278–285, 2005. [23] Z. Jing, J. Caltagarone, and R. Bowser, “Altered subcellu- lar distribution of c-Abl in alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 17, no. 2, pp. 409–422, 2009. [24] M. A. Tremblay, C. M. Acker, and P. Davies, “Tau phospho- rylated at tyrosine 394 is found in Alzheimer’s disease tangles and can be a product of the abl-related kinase, Arg,” Journal of Alzheimer’s Disease, vol. 19, no. 2, pp. 721–733, 2010. [25] P. Derkinderen, T. M. E. Scales, D. P. Hanger et al., “Tyrosine 394 is phosphorylated in Alzheimer’s paired helical ﬁlament tau and in fetal tau with c-Abl as the candidate tyrosine kinase,” Journal of Neuroscience, vol. 25, no. 28, pp. 6584–6593, 2005. [26] A. R. Alvarez, P. C. Sandoval, N. R. Leal, P. U. Castro, and K. S. Kosik, “Activation of the neuronal c-Abl tyrosine kinase by amyloid-β-peptide and reactive oxygen species,” Neurobiology of Disease, vol. 17, no. 2, pp. 326–336, 2004. International Journal of Cell Biology [27] G. I. Cancino, E. M. Toledo, N. R. Leal et al., “STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer’s β-amyloid deposits,” Brain, vol. 131, no. 9, pp. 2425–2442, 2008. [28] A. Klein, C. Maldonado, L. M. Vargas et al., “Oxidative stress activates the c-Abl/p73 proapoptotic pathway in Niemann- Pick type C neurons,” Neurobiology of Disease, vol. 41, no. 1, pp. 209–218, 2011. [29] A. R. Alvarez, A. Klein, J. Castro et al., “Imatinib therapy blocks cerebellar apoptosis and improves neurological symp- toms in a mouse model of Niemann-Pick type C disease,” The FASEB Journal, vol. 22, no. 10, pp. 3617–3627, 2008. [30] D. Y. Jia, Z. H. Du, S. M. Liu et al., “c-Abl is involved in high glucose-induced apoptosis in embryonic E12.5 cortical neural progenitor cells from the mouse brain,” Journal of Neurochem- istry, vol. 106, no. 4, pp. 1720–1730, 2008. [31] J. H. Lee, M. W. Jeong, W. Kim, H. C. Yoon, and K. T. Kim, “Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress,” The Journal of Biological Chemistry, vol. 283, no. 28, pp. 19826–19835, 2008. [32] S. Liu, Q. Yuan, S. Zhao et al., “High glucose induces apoptosis in embryonic neural progenitor cells by a pathway involving protein PKCδ,” Cellular Signalling, vol. 23, no. 8, pp. 1366– 1374, 2011. [33] H. P. Lee, N. Pancholi, L. Esposito, L. A. Previll, X. Wang, X. Zhu et al., “Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity,” PLoS One, vol. 7, Article ID e28033, 2012. [34] Z. I. Alam, A. Jenner, S. E. Daniel et al., “Oxidative DNA dam- age in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1196–1203, 1997. [35] H. S. Ko, Y. Lee, J. H. Shin et al., “Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 38, pp. 16691–16696, 2010. [36] S. Z. Imam, Q. Zhou, A. Yamamoto et al., “Novel regulation of Parkin function through c-Abl-mediated tyrosine phos- phorylation: Implications for Parkinson’s disease,” Journal of Neuroscience, vol. 31, no. 1, pp. 157–163, 2011. [37] A. G. Kanthasamy, M. Kitazawa, S. Kaul et al., “Proteolytic activation of proapoptotic kinase PKCδ is regulated by overexpression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson’s disease,” Annals of the New York Academy of Sciences, vol. 1010, pp. 683–686, 2003. [38] S. Kaul, A. Kanthasamy, M. Kitazawa, V. Anantharam, and A. G. Kanthasamy, “Caspase-3 dependent proteolytic activation of protein kinase Cδ mediates and regulates 1-methyl-4- phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopamin- ergic degeneration,” European Journal of Neuroscience, vol. 18, no. 6, pp. 1387–1401, 2003. [39] C. Brodie and P. M. Blumberg, “Regulation of cell apoptosis by protein kinase c δ,” Apoptosis, vol. 8, no. 1, pp. 19–27, 2003. [40] W. Lu, H. K. Lee, C. Xiang, S. Finniss, and C. Brodie, “The phosphorylation of tyrosine 332 is necessary for the caspase 3-dependent cleavage of PKCδ and the regulation of cell apoptosis,” Cellular Signalling, vol. 19, no. 10, pp. 2165–2173, 2007. [41] A. El Jamali, A. J. Valente, and R. A. Clark, “Regulation of phagocyte NADPH oxidase by hydrogen peroxide through a Ca2+/c-Abl signaling pathway,” Free Radical Biology and Medicine, vol. 48, no. 6, pp. 798–810, 2010.